<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04425148</url>
  </required_header>
  <id_info>
    <org_study_id>2020P000457</org_study_id>
    <nct_id>NCT04425148</nct_id>
  </id_info>
  <brief_title>Gamma-Induction in FrontoTemporal Dementia Trial</brief_title>
  <acronym>GIFTeD</acronym>
  <official_title>Non-invasive Brain Stimulation for Gamma-induction and Cognitive Enhancement in FTD (Gamma-Induction in FrontoTemporal Dementia, GIFTeD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Drug Discovery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, sham controlled, double-blind study designed to investigate the&#xD;
      safety, tolerability and efficacy of 40 Hz transcranial alternating current stimulation&#xD;
      (tACS), a form of noninvasive brain stimulation, delivered for 6 weeks once daily in&#xD;
      frontotemporal dementia (FTD) patients. Cognition, gamma EEG activity and brain metabolism&#xD;
      via FDG-PET will be measured before and after the tACS intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, multi-site, randomized, double-blind, placebo-controlled study of&#xD;
      tACS in patients with FTD. The main aim of this study is to investigate the safety,&#xD;
      tolerability and efficacy of gamma-tACS in patients with behavioral variant (bv)-FTD,&#xD;
      demonstrating tACS potential mechanisms of action, target engagement, and thus informing the&#xD;
      design of larger clinical trials.&#xD;
&#xD;
      Participants will be screened at trial sites for determination of eligibility to enter the&#xD;
      study on the basis of diagnostic evaluations, according to current diagnostic criteria for&#xD;
      probable bv-FTD and safety assessments.&#xD;
&#xD;
      Baseline assessments will consist of behavioral/cognitive evaluations, blood biomarkers,&#xD;
      actigraphy, voice biomarkers, EEG and TMS-EEG and tACS with EEG measures, MRI, FDG-PET&#xD;
      imaging (5-8 visits). Once participants have met all inclusion and exclusion criteria, they&#xD;
      will be randomly assigned to either 6 weeks of daily tACS sessions or 6 weeks of daily Sham&#xD;
      tACS sessions.&#xD;
&#xD;
      Post-intervention visits will include FDG-PET scans, MRI, cognitive testing, tACS with EEG,&#xD;
      blood biomarkers and TMS-EEG (5-8 visits). A follow-up visit will occur 3 months after the&#xD;
      post-invention visit. This visit will include an EEG registration, cognitive testing and&#xD;
      behavioral markers.&#xD;
&#xD;
        -  tACS is a way of stimulating the brain externally using weak electric currents.&#xD;
&#xD;
             -  Electrodes are placed into a cap that you wear on your head.&#xD;
&#xD;
             -  A weak electrical current travels back and forth through the electrodes to your&#xD;
                head.&#xD;
&#xD;
        -  FDG-PET is a way of taking pictures of your brain using a special dye that is absorbed&#xD;
           into your body. In this study, the dye will help us to see the glucose uptake in your&#xD;
           brain. The PET scans for this study will be done at Massachusetts General Hospital&#xD;
           (MGH).&#xD;
&#xD;
        -  TMS is a noninvasive way of stimulating the brain and will be used in this study to&#xD;
           measure your brain's plasticity. Brain plasticity is the brain's ability to change and&#xD;
           learn through experience. TMS uses a magnetic field to cause changes in the brain&#xD;
           activity. The magnetic field is produced by a coil that is held next to your scalp. We&#xD;
           will measure how your brain responds to the TMS before and after the tACS treatment.&#xD;
&#xD;
        -  EEG is used in routine clinical care to measure the brain's electrical activity. EEG&#xD;
           involves placing a cap with electrodes onto your head.&#xD;
&#xD;
      The investigators will enroll a sample of 20 age-matched healthy controls, who will undergo&#xD;
      evaluations similar to the bv-FTD baseline assessment except for PET imaging. Healthy&#xD;
      subjects will not have the tACS intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Attrition (withdrawal) rate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The rate of enrolled participants who withdraw from the study will be reported</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Gamma activity</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Changes in oscillatory activity in the EEG gamma band will be evaluated before and after the tACS sessions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cognition</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Change in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog) score will be reported. The score ranges from 0-85 with the higher score meaning greater cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Cognition</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Change in Frontal Assessment Battery (FAB) score will be reported. The scores range from 0-18 with a higher score meaning less cognitive impairment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Brain Metabolism measured via FDG-PET</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Change in brain glucose metabolism will be measured via FDG-PET after the daily tACS sessions</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Frontotemporal Dementia</condition>
  <arm_group>
    <arm_group_label>tACS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 Hz transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tACS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham transcranial alternating current stimulation (tACS), 30 daily (Monday-Friday) 1-hour sessions</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Alternating Current Stimulation (tACS)</intervention_name>
    <description>tACS is a noninvasive way of stimulating the brain externally using weak electric currents. Electrodes are placed into a cap that you wear on your head. A weak electrical current travels back and forth through the electrodes to your head.</description>
    <arm_group_label>tACS</arm_group_label>
    <other_name>Non-invasive Brain Stimulation</other_name>
    <other_name>Neuroelectrics Starstim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Transcranial Alternating Current Stimulation (sham tACS)</intervention_name>
    <description>Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.</description>
    <arm_group_label>Sham tACS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        FTD Participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of probable Frontotemporal dementia (bvFTD)&#xD;
&#xD;
          -  Mini Mental State Examination (MMSE) &gt; 18&#xD;
&#xD;
          -  FTLD-specific Clinical Dementia Rating (FTLD-CDR) total score of â‰¤1&#xD;
&#xD;
          -  On stable medications related to cognition or behavior for &gt;30 days such as&#xD;
             acetylcholinesterase inhibitors, memantine, anti-depressants, antipsychotic agents,&#xD;
             other mood stabilizers, benzodiazepines;&#xD;
&#xD;
          -  Age from 40 to 80 years;&#xD;
&#xD;
          -  Minimum of completed 8th grade education&#xD;
&#xD;
          -  No history of intellectual disability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or past history of any significant neurodegenerative disorder of the central&#xD;
             nervous system other than FTD e.g. Alzheimer's disease, Lewy body dementia,&#xD;
             Parkinson's disease, multiple sclerosis, progressive supranuclear palsy, normal&#xD;
             pressure hydrocephalus, Huntington's disease, any condition directly or indirectly&#xD;
             caused by Transmissible Spongiform Encephalopathy (TSE), Creutzfeldt-Jakob Disease&#xD;
             (CJD), variant Creutzfeldt-Jakob Disease (vCJD), or new variant Creutzfeldt-Jakob&#xD;
             Disease (nvCJD);&#xD;
&#xD;
          -  Current or past history of stroke (cortical stroke), intracranial brain lesions,&#xD;
             previous neurosurgery or head trauma that resulted in residual neurologic impairment.&#xD;
&#xD;
               -  Non-cortical disease such as confluence white matter changes (including lacunar&#xD;
                  infarcts &lt; 1cm) and asymptomatic, subacute, cerebellar infarcts may be included&#xD;
                  upon review of a medically responsible neurologist.&#xD;
&#xD;
          -  Past or current history of major depression, bipolar disorder, psychotic disorders, or&#xD;
             any other major psychiatric condition will be evaluated by the study MD.&#xD;
&#xD;
          -  Current history of poorly controlled migraines including chronic medication for&#xD;
             migraine prevention&#xD;
&#xD;
          -  History of seizures with the exception of a single seizure of benign etiology (e.g.&#xD;
             febrile seizure) in the judgment of the investigator;&#xD;
&#xD;
          -  History of fainting spells of unknown or undetermined etiology that might constitute&#xD;
             seizures.&#xD;
&#xD;
          -  Chronic (particularly) uncontrolled medical conditions that may cause a medical&#xD;
             emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia,&#xD;
             asthma, etc.).&#xD;
&#xD;
          -  Metal implants in the head (except dental), pacemaker, medication pump, nerve&#xD;
             stimulator, TENS unit, ventriculo-peritoneal shunt, cochlear implant, unless cleared&#xD;
             by the study MD.&#xD;
&#xD;
          -  Contraindication for undergoing MRI or receiving TMS or tACS;&#xD;
&#xD;
          -  Any clinically significant hematological, endocrine, cardiovascular, renal, hepatic,&#xD;
             gastrointestinal or neurological disease. If the condition has been stable for at&#xD;
             least the past year and is judged by the investigator not to interfere with the&#xD;
             patient's participation in the study, the patient may be included;&#xD;
&#xD;
          -  &gt;50 mSv of radiation exposure for research within the past year (PET imaging&#xD;
             exclusion);&#xD;
&#xD;
          -  Substance abuse or dependence within the past six months;&#xD;
&#xD;
          -  Medications will be reviewed by the responsible MD and a decision about inclusion will&#xD;
             be made based on the following: The patient's past medical history, drug dose, history&#xD;
             of recent medication changes or duration of treatment, and combination of CNS active&#xD;
             drugs;&#xD;
&#xD;
          -  All female participants that are pre-menopausal will be required to have a pregnancy&#xD;
             test; any participant who is pregnant or breastfeeding will not be enrolled in the&#xD;
             study;&#xD;
&#xD;
          -  Subjects who, in the investigator's opinion, might not be suitable for the study;&#xD;
&#xD;
          -  A hair style or head dress that prevents electrode contact with the scalp or would&#xD;
             interfere with the stimulation (for example: thick braids, hair weave, afro, wig).&#xD;
&#xD;
        Healthy Volunteers&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 40-80 years&#xD;
&#xD;
          -  Normal healthy volunteer&#xD;
&#xD;
          -  Right-handed (assessed by means of the Edinburgh Handedness Questionnaire)&#xD;
&#xD;
          -  MMSE &gt;27&#xD;
&#xD;
          -  Minimum of completed 8th grade education&#xD;
&#xD;
          -  No history of intellectual disability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of fainting spells of unknown or undetermined etiology that might constitute&#xD;
             seizures&#xD;
&#xD;
          -  History of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or&#xD;
             family history of treatment resistant epilepsy, with the exception of a single seizure&#xD;
             of benign etiology (e.g. febrile seizures) in the judgment of the investigator&#xD;
&#xD;
          -  History of head injury resulting in prolonged loss of consciousness&#xD;
&#xD;
          -  Any metal in the brain, skull or elsewhere unless approved by the responsible MD&#xD;
&#xD;
          -  Any medical devices (i.e. Cardiac pacemaker, deep brain stimulator, medication&#xD;
             infusion pump, cochlear implant, vagal nerve stimulator) unless otherwise approved by&#xD;
             the responsible MD&#xD;
&#xD;
          -  Past or current history of major depression, bipolar disorder or psychotic disorders,&#xD;
             or any other major psychiatric condition.&#xD;
&#xD;
          -  Neurological disorder or intracranial lesion (including an incidental finding on MRI)&#xD;
&#xD;
          -  Current history of poorly controlled migraines including chronic medication for&#xD;
             migraine prevention&#xD;
&#xD;
          -  Any unstable medical condition&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Medications will be reviewed by the responsible MD and a decision about inclusion will&#xD;
             be made based on the following:&#xD;
&#xD;
               -  The participant's past medical history, drug dose, history of recent medication&#xD;
                  changes or duration of treatment, and combination with other CNS active drugs.&#xD;
&#xD;
          -  Substance abuse or dependence within the past six months&#xD;
&#xD;
          -  Subjects who, in the investigator's opinion, might not be suitable for the study&#xD;
&#xD;
          -  Diseased or damaged skin over the face or scalp&#xD;
&#xD;
          -  A hair style or head dress that prevents electrode contact with the scalp (for&#xD;
             example: thick braids, hair weave, afro, wig)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emiliano Santarnecchi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan Hoffman</last_name>
    <phone>617-667-9088</phone>
    <email>mahoffma@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Molly O'Reilly</last_name>
    <phone>617-667-0249</phone>
    <email>moreill1@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Hoffman</last_name>
      <phone>617-667-9088</phone>
      <email>mahoffma@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Molly O'Reilly</last_name>
      <phone>617-667-0249</phone>
      <email>moreill1@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione Santa Lucia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caterina Motta</last_name>
      <email>c.motta@hsantalucia.it</email>
    </contact>
    <investigator>
      <last_name>Giacomo Koch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 1, 2020</study_first_submitted>
  <study_first_submitted_qc>June 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Emiliano Santarnecchi</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>FTD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

